|Day Low/High||43.35 / 43.62|
|52 Wk Low/High||33.20 / 43.68|
Pfizer Inc. (NYSE:PFE) announced today that additional sensitivity and post-hoc analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) study provide further detail on the effect of tafamidis across wild-type, hereditary, and...
Pfizer Inc. (NYSE:PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia...
The most recent short interest data has been released for the 08/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D'Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley 16 th Annual Global Healthcare Conference on...
Pfizer Inc. (NYSE:PFE) today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.
Biotechs are known for wild tears. Investors, you'll want to consider these drug makers.
Pfizer Inc. (NYSE: PFE) today announced the pricing of a debt offering consisting of six tranches of notes: $300,000,000 aggregate principal amount of floating rate notes due 2023 $1,000,000,000 aggregate principal amount of 3.
Pfizer Inc. (NYSE: PFE) announced today that it is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD): a Phase 2 safety and efficacy study (B5161002) and an open-label...
Markets were higher Tuesday after starting Tuesday's session off in the green.
The S&P 500 and Nasdaq set record highs as stocks rose Monday after the U.S. and Mexico reached a tentative trade agreement.
Pfizer Inc. (NYSE:PFE) announced today the primary results from the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study, which showed tafamidis significantly reduced the hierarchical combination of both all-cause mortality and frequency of...
A 'bullish perfect storm of technical factors' is powering the recent strength in large-cap pharma stocks, says Evercore ISI's Rich Ross.
Jim Cramer explains the art and science of technical analysis. Plus, he has next week's game plan.
Jim Cramer says we have a $19 trillion economy, and two-thirds of it is based on consumer spending -- not manufacturing, or sales, or industry.
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
Amendments accelerate anticipated primary completion dates for both ARCHES and EMBARK trials
Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc.
Collaboration is expected to drive Cologuard adoption through expanded sales and marketing efforts
Traders should raise sell stops to just above $40 from below $35.50
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts on Monday, August 27, 2018 at 9:00 a.
Thanks, Omarosa. And you too, Bob Mueller, for distracting the president this week from trade wars and tariff skirmishes and allowing investors to make some money.
Walmart -- with great growth -- sparks optimism, but Jim Cramer says it's not the only stock to fuel the day's rally.
Retail earnings are in full swing with results from Walmart and J.C. Penney. All eyes still on the cannabis space. Big day for tool king Stanley Black & Decker.
Take a pass on stocks like Kimberly-Clark or Pfizer that are bucking Wednesday's sell-off and going higher.
Time to brace for a summer pullback?
The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.